Cargando…
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability
PURPOSE: Chronic Myeloid Leukemia (CML) is a clonal disorder of the hematopoietic stem cell caused by expression of the BCR::ABL1 oncoprotein. High BCR::ABL1 levels have been associated to proliferative advantage of leukemic cells, blast crisis progression and tyrosine kinase inhibitors (TKIs) ineff...
Autores principales: | Massimino, Michele, Stella, Stefania, Tirrò, Elena, Pennisi, Maria Stella, Stagno, Fabio, Vitale, Silvia Rita, Romano, Chiara, Tomarchio, Cristina, Parrinello, Nunziatina Laura, Manzella, Livia, Di Raimondo, Francesco, Vigneri, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559794/ https://www.ncbi.nlm.nih.gov/pubmed/37807980 http://dx.doi.org/10.2147/OTT.S413825 |
Ejemplares similares
-
Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells
por: Massimino, Michele, et al.
Publicado: (2021) -
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
por: Massimino, Michele, et al.
Publicado: (2021) -
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
por: Massimino, Michele, et al.
Publicado: (2018) -
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019) -
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
por: Tirrò, Elena, et al.
Publicado: (2019)